Abstract:
A peptide fraction inducing the formation of antibodies which protect against the bovine leukemia virus (BLV), wherein it includes a peptide sequence which reproduces all or part of the sequence of the glycoprotein envelope gp51 fragment of the BLV virus which bears at least one of the epitopes (F, G, H) responsible for the biological activity of the virus. This fraction may be the fragment itself or a synthetic peptide. Application is made to the preparation or search for antibodies, to diagnosis and to the preparation of vaccines.
Abstract:
A human endogenous retrovirus-related Mv-75,000 protein, containing the decapeptide sequence Glutamic Acid-Asparagine-Proline-Serine-Glutamine-Phenylalanine-Tyrosine-Glutamic Acid-Arginine-Leucine, a synthetic undecapeptide Sp-23 based on the decapeptide, and specific polycolonal and monoclonal antibodies and specific nucleic acid probes are used as specific reagents for the detection and treatment of tumors such as renal cell adenocarcinoma and choriocarcinoma, among others, and placental disorders including blighted ova, hydatiform and destructive moles.
Abstract:
An antibody of a human leukemia virus-related peptide obtained by collecting an antibody produced in a mammal body by administering to the mammal an antigen prepared by reacting a human leukemia virus-related peptide represented by formula (1):R-Pro-Val-Met-His-Pro-His-Gly-Ala-Pro-OH (1)whereinR is a hydrogen atom or a group shown by formula, H-Tyr-;as a hapten, with a carrier in the presence of a hapten-carrier binding agent.
Abstract:
A new immunodiffusion test method for determining the presence of bovine leukemia viral infection in cattle.The method relies upon the formation of a precipitin line resulting from the reaction of glycoprotein antigen with an antibody. The reaction is conducted in a liquid gel medium. By comparing the precipitin line of this test against a standard the presence of bovine leukemia infection can be diagnosed.Also covered is the immunological composition comprising said antigen and said liquid gel media.
Abstract:
本発明はHERV−Wエンベロープタンパク質(envelope protein (ENV))、特にそのMSRVサブタイプの発現に関連する各種疾患において成人神経系(nervous system (NS))の内在性ミエリン修復能力を遮断する、新たに発見された有害なメカニズムを予防し、及び/又は治療するための革新的化合物および組成物に関する。
Abstract:
The present invention provides for isolated nucleic acid sequences encoding viruses; isolated polypeptides comprising amino acid sequences of the virus; vectors comprising the viral nucleic acid sequences; cells comprising the vectors; antibodies and antigen binding fragments thereof which have binding specificity for the virus; methods of detecting or screening for the virus (e.g., in an individual); methods of identifying agents that inhibit the virus; methods of inducing an immune response to the virus; methods of treating disease associated with the presence of XMRV in an individual (e.g., cancer such as prostate cancer); methods of detecting asymptomatic cancer (e.g., prostate cancer); methods of identifying an individual at risk for developing cancer (e.g., prostate cancer); and kits for detecting the virus.
Abstract:
NEW MATERIAL:A monoclonal antibody having specific reactivity to human addult T-cell leukemia-associated antigens (ATLA), produced by a fused cell of a mammalian immunocyte immunized with a human addult T-cell leukemia virus and a mammalian myeloma cell. EXAMPLE:An ATLA antibody. USE:A diagnosticum and remedy for human adult T-cell leukamia. PROCESS:A human adult T-cell leukemia virus (ATLV) and Freund's auxiliary solution are made into a suspension, administered to a mammal such as mouse, etc. by hypodermic injection, etc., so that it is immunized. Three days after final immunization, its spleen is extracted, to give a splenic cell. It is blended with a myeloma cell of mouse, etc., and subjected to cell fusion to prepare hybridoma, which is coloned. A monoclonal cell is cultivated, to give an ATLA antibody.